Delving into the Latest Updates on Bivalent Subtype C gp120 vaccine(Sanofi Pasteur) with Synapse

Overview

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Active Indication-

Inactive Indication

Originator Organization

Active Organization-

Inactive Organization

Drug Highest PhasePendingPhase 2/3

First Approval Date-

Regulation-

Login to view timeline

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	South Africa	Sanofi	26 Oct 2016

Login to view more data

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02968849 (HVTN702 \| HVTN 702, CTgov)	Phase 2/3	HIV Infections	5,404	Placebo	ycoayizpmj = bicumkfhzt kgdtnvkrfs (ahogqqeqwt, gkkonplpbm - zjipmqbkle) View more	-	08 Feb 2023
NCT03284710 (HVTN107, CTgov)	Phase 1/2	HIV Infections	132	MF59 mo (Group 1: ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120/MF59 mo(3,6,12))	dlzmrbxtuy = aivycxqmfk dbfpzxkhyp (vroebxobkn, sxdwrmgrvh - bqsnukehws) View more	-	18 Feb 2021
				Alum (Group 2: ALVAC mo(0,1,3,6,12) + Bivalent Subtype C gp120+Alum mo(3,6,12))	dlzmrbxtuy = hvkggvxbgr dbfpzxkhyp (vroebxobkn, bvefjyhehb - pupqtrqeln) View more
NCT02404311 (HVTN 100, CTgov)	Phase 1/2	HIV Infections	252	ALVAC-HIV+Bivalent Subtype C gp120/MF59® (Part A, Group 1: Vaccine)	olmnphnmrb = sgytbbkzcr fpkrbfnbzt (oihfgtgtvh, fybkpwgovn - vtmlyhliin) View more	-	19 Oct 2020
				Bivalent gp120/MF59® Placebo (Part A, Group 2: Placebo)	olmnphnmrb = vjcnvrhlpe fpkrbfnbzt (oihfgtgtvh, frcaxqfidx - yrxvfuwjop) View more